Actively Recruiting
Evaluation of 68Ga-XHER2 PETCT Imaging for Noninvasive HER2 Expression Assessment in Solid Tumors
Led by The First Affiliated Hospital of Xiamen University · Updated on 2026-10-21
80
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of 68Ga-XHER2 PETCT imaging to noninvasively assess HER2 expression in patients with various solid tumors. The study aims to determine how well this imaging method correlates with the standard pathological assessment of HER2 in tumor tissues, helping to understand its feasibility across different cancer types. Participants will receive a single intravenous injection of 68Ga-XHER2, a new HER2-targeted PET tracer, followed by PETCT imaging. The study measures tumor uptake using the maximum standardized uptake value SUVmax and compares it to HER2 expression determined by immunohistochemistry IHC. This approach helps evaluate if PETCT imaging can reliably reflect HER2 levels in tumors without the need for invasive biopsies. During the study, participants undergo the PETCT scan after tracer injection and provide informed consent. Researchers collect imaging data and tissue pathology results to analyze the correlation between tracer uptake and HER2 expression. The primary outcome is assessing the feasibility of this imaging method within one month, with secondary outcomes including detailed descriptions of tracer uptake in different tumors. The study is sponsored by The First Affiliated Hospital of Xiamen University and involves adults aged 18 years and older.
CONDITIONS
Brief Title
68Ga-XHER2 PET/CT for HER2 Assessment
Research Team
L
Liang Zhao, MD, PhD
H
Haojun Chen, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here